CASE REPORT

Sporadic ALS with compound heterozygous mutations in the *SQSTM1* gene

**Hiroshi Shimizu · Yasuko Toyoshima · Atsushi Shiga · Akio Yokoseki ·
Keiko Arakawa · Yumi Sekine · Takayoshi Shimohata · Takeshi Ikeuchi ·
Masatoyo Nishizawa · Akiyoshi Kakita · Osamu Onodera · Hitoshi Takahashi**

Abstract Accumulating evidence suggests that heterozygous mutations in the *SQSTM1* gene, which encodes p62 protein, are associated with amyotrophic lateral sclerosis (ALS). Here, we report a Japanese patient with sporadic, late-onset ALS who harbored compound heterozygous *SQSTM1* mutations (p.[Val90Met];[Val153Ile]). Autopsy examination revealed that although TDP-43 pathology was rather widespread, the selective occurrence of p62-positive/TDP-43-negative cytoplasmic inclusions in the lower motor neurons (LMNs) was a characteristic feature. No Bunina bodies were found. Ultrastructurally, p62-positive cytoplasmic inclusions observed in the spinal anterior horn cells were composed of aggregates of ribosome-like granules and intermingled bundles of filamentous structures. Another feature of interest was concomitant Lewy body pathology. The occurrence of distinct p62 pathology in the LMNs in this patient indicates the pathogenic role of *SQSTM1* mutations in the development of a subset of ALS.

Introduction

A number of genes, including *SOD1* [4, 16], *TARDBP* (*TDP-43*) [18, 22], *FUS* [9, 21], *UBQLN2* [5], and *C9Orf72* [3, 15] have been identified as the causative genes for familial or sporadic amyotrophic lateral sclerosis (ALS). Recently heterozygous mutations in the sequestosome 1 (*SQSTM1*) gene, which encodes p62 and is one of the causative genes for Paget disease of bone (OMIM#602080), have been reported to be associated with ALS and frontotemporal lobar degeneration (FTLD) [6, 7, 17]. Very recently, autopsy findings of three patients with heterozygous mutations of *SQSTM1* gene have also been reported [20]. However, rare variants of *SQSTM1* have also been observed in normal control individuals [6, 17, 20]. Therefore, it remains obscure whether the *SQSTM1* mutations found in patients with ALS/FTLD are causative of ALS/FTLD [6, 7, 17, 20].

Here, we report the clinicopathological features of a 75-year-old Japanese man with sporadic, late-onset ALS without dementia who harbored compound heterozygous mutations in the *SQSTM1* gene. The distinct p62 pathology observed in the lower motor neurons (LMNs) appeared to be important when considering the role of *SQSTM1* mutations in the development of ALS.

Patient and methods

The present study was conducted in the frame of a study "Neuropathological and Molecular-Genetic investigation of

H. Shimizu · Y. Toyoshima · A. Shiga · A. Kakita ·
H. Takahashi (✉)
Department of Pathology, Brain Research Institute, University
of Niigata, 1-757 Asahimachi, Chuo-ku, Niigata 951-8585, Japan
e-mail: hitoshi@bri.niigata-u.ac.jp

A. Yokoseki · K. Arakawa · Y. Sekine · T. Shimohata · T. Ikeuchi ·
M. Nishizawa
Department of Neurology, Brain Research Institute,
University of Niigata, Niigata, Japan

O. Onodera
Department of Molecular Neuroscience, Brain Research Institute,
University of Niigata, Niigata, Japan

🖄 Springer

CNS Degenerative Diseases" approved by the Institutional Review Board of the University of Niigata.

Patient

The patient became aware of weakness of both hands at the age of 72 years. Over the next 6 months, he developed muscle weakness, atrophy and fasciculation in the trunk and all four extremities. On examination, deep tendon reflexes were decreased. Electromyography showed neurogenic changes in the muscles of the upper and lower extremities as well as the tongue. He was then diagnosed as having ALS. His serum IgG level was 1,754 mg/dl (normal value 870–1,700 mg/dl), soluble interleukin 2 receptor (sIL-2R) level was over 5,500 U/ml (normal value 190–650 U/ml), and the presence of M-protein was noted, leading to a diagnosis of concomitant multiple myeloma of the IgG kappa type. The weakness progressed slowly and steadily; even in the late stage, although dyspnea became evident, the patient was able to walk a short distance. Moreover, bulbar symptoms, such as dysphagia, were not evident. He died of respiratory failure at the age of 75. Babinski reflex was first elicited 1 month before death. Dementia, extrapyramidal signs, or autonomic failure were not noted throughout the illness. There were no symptoms or laboratory findings suggestive of Paget disease of bone. There was no history of similar neurological disorders or dementia in the patient's family members, including the parents and five siblings. A general autopsy was performed 1 h after death, at which time the brain weighed 1,315 g. Both lungs showed mild bronchopneumonia.

Neuropathological examination

The brain and spinal cord were fixed with 20 % buffered formalin for 40 days, and multiple tissue blocks were embedded in paraffin. Histological examinations were performed on 4-μm thick sections using several stains, including hematoxylin and eosin and Klüver–Barrera. In each anatomical region, the severity of neuron loss was graded according to the percentage of the lost neurons: −, none; +, less than 40 %; ++, 40–70 %; +++, more than 70 %.

For immunohistochemistry, 4-μm thick selected sections were incubated overnight at 4 °C with one of the primary antibodies listed in Table 1. Pretreatment, if necessary, was performed by heat/autoclaving for 10 min at 121 °C or in a microwave oven for 30 min at 90 °C (both in 10 mM sodium citrate buffer), or in formic acid for 5 min. Bound antibodies were visualized by the peroxidase-polymer-based method using a Histofine Simple Stain MAX-PO kit (Nichirei, Tokyo, Japan) with diaminobenzidine as the chromogen. Immunostained sections were counterstained with hematoxylin. In each anatomical region, the numbers of neuronal cytoplasmic inclusions (NCIs) and glial cytoplasmic inclusions (GCIs), as well as α-synuclein-positive Lewy bodies, were counted per ×100 power field, and graded as follows: −, absent; +, ~2 inclusions; ++, 3–5 inclusions; +++, more than 5 inclusions. In addition, some selected p62-immunostained sections were recycled for conventional electron microscopy.

For double-labeling immunofluorescence study, selected sections were similarly pretreated in a microwave oven and immunostained with monoclonal anti-p62 (1:500), polyclonal anti-ubiquitin (1:400) or anti-TDP-43 (1:2,000). The second antibodies used were Alexa Fluor 555 goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA; 1:1,000) and Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes; 1:1,000). Slides were treated with an Autofluorescence Eliminator Reagent (Millipore, Billerica, MA, USA), mounted with glass coverslips using VECTAshield mounting medium with 4,6-diamidino-2-phenylindole (DAPI) nuclear stain (Vector Laboratories, Burlingame, CA, USA), and analyzed using a confocal laser-scanning microscope.

Table 1 List of antibodies

Primary antibodies	Host	Dilution	Pretreatment	Source
p62 (3/p62 LCK LIGAND)	m (mc)	1:1,000	Microwave	BD Biosciences, San Jose, CA, USA
TDP-43 (10782-1-AP)	r (pc)	1:4,000	Heat/autoclaving	ProteinTec Group Inc., Chicago, IL, USA
pTDP-43 (pS409/410)	m (mc)	1:3,000	Heat/autoclaving	Cosmo Bio Co., Ltd, Tokyo, Japan
Ubiquitin	r (pc)	1:800	–	Dako, Glostrup, Denmark
Ubiquilin 2 (5F5)	m (mc)	1:10,000	Heat/autoclaving	Novus Biologicals, Litlleton, CO, USA
Phosphorylated α-synuclein (#64)	m (mc)	1:10,000	Formic acid	Wako, Osaka, Japan

m (mc), mouse (monoclonal); r (pc) rabbit (polyclonal)

Mutational analysis of SQSTM1

High molecular weight genomic DNA was extracted after obtaining informed consent from the patient's family members. We amplified all the exons of *SQSTM1* (NM_003900.4) using a series of primers, followed by sequence reaction. In 189 unrelated healthy control subjects, we assessed the presence or absence of the two substitutions in *SQSTM1* identified in the present case, using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA).

Results

Neuropathological findings

The brain appeared normal in external appearance. In sections, mild depigmentation of the substantia nigra and locus ceruleus was noted. The spinal cord and anterior roots were atrophic.

Histological examination revealed that the patient had LMN-predominant ALS. The lateral corticospinal tracts of the spinal cord showed mild degeneration (Fig. 1a). The motor cortex also showed mild loss of Betz cells, as evidenced by the presence of a few Betz cell-sized holes containing lipofuscin-laden macrophages. In the spinal cord and brainstem, varying degrees of LMN loss were observed, being severe in the cervical anterior horns, moderate in the lumbar anterior horns (Fig. 1b), and much milder in the hypoglossal and facial nerve motor nuclei (Fig. 1c). No Bunina bodies were found. The diaphragm showed severe neurogenic muscular atrophy.

Immunohistochemically, large p62-positive NCIs were observed in the LMNs (Fig. 1d). p62-positive "skein-like" NCIs were extremely rare (Fig. 1e). Although less frequently, p62-positive inclusions were also observed in the swollen cell processes (dystrophic neurites) of LMNs, as well as the cytoplasm of glial (oligodendrocytic) cells (GCIs) (Fig. 1f). However, in the LMN nuclei, including the spinal anterior horns, no NCIs or GCIs positive for TDP-43 or phosphorylated TDP-43 (pTDP-43) were evident. Moreover, the LMNs retained endogenous nuclear staining for TDP-43. Immunostaining performed on serial sections confirmed that p62-positive NCIs in the LMNs were negative for TDP-43 (Fig. 1g), pTDP-43, and ubiquilin 2. Double-labeling immunofluorescence also demonstrated that p62-positive NCIs in LMNs were negative for ubiquitin (Fig. 1h) and TDP-43 (Fig. 1i). Ultrastructurally, p62-positive NCIs appeared as aggregates of ribosome-like granules containing scattered bundles of filamentous structures (Fig. 1j). p62-positive NCIs were also present in non-motor neurons. In the pontine, cerebellar dentate and subthalamic nuclei, where no neuronal loss was evident, a few p62-positive NCIs and/or GCIs were found (Fig. 1k). Immunostaining for TDP-43 or ubiquitin showed no positive NCIs or GCIs in these regions.

In the other CNS regions, however, small numbers of TDP-43-positive NCIs, dystrophic neurites and GCIs were encountered (Fig. 1l). The hippocampal dentate granule cells showed no such lesions, and the distribution pattern of TDP-43-positive NCIs was reminiscent of that in ALS (Type 1), except for virtual sparing of LMNs [14]. Although less frequent, p62-positive inclusions similar in morphology and distribution to the TDP-43-positive inclusions were also detected, whereas no such inclusions were detectable by ubiquitin immunohistochemistry.

Cerebral cortical TDP-43 pathology was mild, some NCIs and fewer dystrophic neurites being evident in the frontal lobe, and classifiable as 'Type B' [10]. The hippocampal and cerebellar p62/ubiquilin 2 pathology seen in ALS with *C9orf72* mutations [1, 2, 13] was not evident in the present patient.

In addition, concomitant Lewy body pathology was also present; the patient was considered to have Parkinson's disease (PD). Neuronal loss and gliosis were noted in the substantia nigra, locus ceruleus, and dorsal vagal nucleus. Lewy bodies positive for α-synuclein, ubiquitin and p62 were widespread in the CNS, including the above-mentioned regions (Fig. 1m–o); the α-synuclein pathology was classified as 'limbic type' [11].

The histological and immunohistochemical findings are summarized in Table 2 [22].

Mutation detection

Because of the distinct pathological features revealed by p62 immunostaining, we performed sequence analysis of the *SQSTM1* gene and found two single base-pair substitutions: one at position 268 from G to A (c.268G>A) in exon 2, which resulted in a Val-to-Met substitution at position 90 (p.Val90Met) in the PB1 domain (Fig. 2a), and the other at position 457 from G to A (c.457G>A) in exon 3, which resulted in a Val-to-Ile substitution at position 153 (p.Val153Ile) in the ZZ-type zinc finger domain (Fig. 2b). Sequence analysis of the PCR fragments spanning exons 2 and 3 revealed that these substitutions were located in different alleles. We confirmed that neither p.Val90Met nor p.Val153Ile mutation of *SQSTM1* was present in any of 189 unrelated healthy individuals (378 chromosomes). PolyPhen2 predicted that the p.Val90Met and p.Val153Ile substitutions were possibly damaging and benign, respectively. No mutations were found in other genes associated with ALS, including *TDP-43*, *VCP*, *C9Orf72* or *CHMP2B*.

Fig. 1 a The cervical cord (C4), showing evident atrophy of the gray matter. Degeneration of the corticospinal tracts (both anterior and lateral) is not evident. b The lumbar anterior horn, showing several remaining lower motor neurons (LMNs). c The facial motor nucleus, showing relatively well-preserved LMNs. d Two p62-positive cytoplasmic inclusions are evident in a lumbar LMN: large (*upper right*) and small ones (*lower left*). e p62-positive skein-like inclusions are evident in a lumbar LMN. Two serial sections containing the facial motor nucleus, showing that p62-positive cytoplasmic inclusions in two LMNs (f) are negative for TDP-43 (g). Two p62-positive swollen cell processes (*arrows*), presumably those of LMNs, are evident (f). A glial cell possessing a p62-positive cytoplasmic inclusion is also shown (f, *inset*). Note that a LMN bearing p62-positive inclusions (f, *lower right*) retains endogenous TDP-43 nuclear staining (g, *asterisk*). Double-labeling immunofluorescence. p62-positive NCIs in a hypoglossal nucleus neuron are negative for ubiquitin (h). p62-positive NCIs in a neuron in the lumbar anterior horn are nega-

tive for TDP-43; note the preservation of endogenous TDP-43 nuclear staining (i). Nuclei were stained with DAPI (*blue*) (h, i). j Recycled electron microscopy specimen of the area indicated by the *upper right open square* in d, demonstrating aggregates of ribosome-like granules and intermingled bundles of filamentous structures (*arrowheads*). Higher-magnification view of the area indicated by the *asterisk*, showing the filamentous structures (*inset*). k p62-positive NCIs are evident in a subthalamic nucleus neuron. l A neuron with pTDP-43-positive inclusions (*lower*) and a glial cell with a cytoplasmic inclusion (*upper*) observed in the frontal cortex. m A typical Lewy body with an eosinophilic core and a peripheral halo in a substantia nigra pigmented neuron. n A phosphorylated α-synuclein-positive Lewy body in a neuron in the midbrain reticular formation. o p62-positive Lewy bodies in a neuron in the medullary reticular formation. *KB* Klüver–Barrera, *HE* hematoxylin and eosin. *Bars* 1 mm for a; 100 μm for b, c; 20 μm for d, e, h, i, k–o; 40 μm for f, g; 2 μm for j; 500 nm for j (*inset*)

Table 2 Summary of neuropathological findings

	Neuron loss	p62		pTDP-43		Ubiquitin		pα-Syn
		NCIs	GCIs	NCIs	GCIs	NCIs	GCIs	LBs
Cerebral cortex								
Frontal	−	+	+	+	+	+ (*LBs)	−	+
Motor	+	+	+	++	++	−	−	+
Insular	−	+ (*LBs)	+	+	+	+ (*LBs)	−	+
Temporal	−	+	+	+	+	+ (*LBs)	−	+
Occipital	−	−	−	−	−	−	−	−
Subcortical area								
Ammon	−	+	+	+	+	−	−	−
Dentate gyrus	−	−	−	−	−	−	−	−
Amygdaloid nuclei	−	+ (*LBs)	+	−	+	+ (*LBs)	−	++
Putamen	−	+	+	+	+	−	−	−
Globus pallidus	−	+	+	+	−	−	−	−
Thalamus	−	+	+	++	+	+ (*LBs)	−	+
Subthalamic nucleus	−	+	+	−	−	−	−	−
Basal nucleus of Meynert	−	++ (*LBs)	−	−	−	++ (*LBs)	−	+++
Brainstem								
Superior colliculus	−	−	−	+	+	−	−	−
Oculomotor nucleus	−	−	−	−	−	−	−	−
Red nucleus	−	+	++	+	++	−	−	−
Substantia nigra	+	+	+	+	+	+ (*LBs)	−	+
Facial nucleus	+	++	+	−	−	−	−	−
Pontine nucleus	−	+	−	−	−	−	−	−
Locus ceruleus	++	+ (*LBs)	−	−	−	+ (*LBs)	−	++
Hypoglossal nucleus	+	+	−	−	−	−	−	−
Dorsal vagal nucleus	+	++ (*LBs)	−	−	−	++ (*LBs)	−	+++
Ambiguus nucleus	−	−	−	−	−	−	−	−
Medullary reticular formation	−	+	+	+	+	+ (*LBs)	−	++
Inferior olivary nucleus	−	+	+	+	+	+	−	−
Cerebellum								
Cerebellar cortex	−	−	−	−	−	−	−	−
Dentate nucleus	−	+	−	−	−	−	−	−
Spinal cord								
Cervical anterior horn	+++	++	+	−	−	−	−	−
Lumbar anterior horn	++	++	+	−	−	−	−	−
Intermediate lateral nucleus	−	+ (*LBs)	−	−	−	−	−	+
Clarke nucleus	−	−	−	−	−	−	−	−

pTDP-43 phosphorylated TDP-43, *pα-Syn* phosphorylated α-Synuclein, *NCIs* neuronal cytoplasmic inclusions, *GCIs* glial cytoplasmic inclusions, *LBs* Lewy bodies

* LBs, p62- or ubiquitin-positive NCIs were mostly Lewy bodies. See "Neuropathological examination" for the grading of neuron loss and inclusions

Discussion

We have described a sporadic, late-onset, pathologically LMN-predominant ALS, carrying compound heterozygous mutations in the *SQSTM1* gene. We have also presented several lines of evidence suggesting that the

SQSTM1 mutations may be pathogenic for ALS. First, both mutations were absent in 378 chromosomes among Japanese controls, as well as in all controls studied previously [6, 7, 17, 20]. Second, p.Val153Ile mutation has been identified previously in two ALS patients [6]. The other mutation, p.Val90Met, is a novel mutation, and in

Fig. 2 Two heterozygous mutations in the *SQSTM1* gene detected in the present patient. **a** One mutation located in exon 2 (c.268G>A) results in a Val-to-Met substitution at position 90 (p.Val90Met). **b** The other mutation located in exon 3 (c.457G>A) results in a Val-to-Ile substitution at codon 153 (p.Val153Ile). The valine residues at positions 90 (**c**) and 153 (**d**) are well and relatively well conserved, respectively, in several species

silico analysis predicted that this mutation may be harmful. Third, Val residues at positions 90 and 153 are well and relatively well conserved evolutionarily, respectively (Fig. 2c, d). Finally and most importantly, the neuropathological features of the LMNs in the present case were associated with p62 and quite distinct from those of sporadic ALS.

In sporadic ALS, it is well known that NCIs positive for ubiquitin, p62 and TDP-43 [8, 14], as well as Bunina bodies, are a feature of the remaining LMNs [12]. During the preparation of this manuscript, a related study was published, showing that all of the present cellular pathological alterations were observed in LMNs of three autopsied ALS patients with heterozygous *SQSTM1* mutations [20]. However, in the LMNs of the present ALS patient with compound heterozygous *SQSTM1* mutations, NCIs positive for only p62 were observed, and Bunina bodies were absent. These results suggest that the neuropathological features of ALS with *SQSTM1* mutations might be heterogeneous. However, it is noteworthy that there is a significant positive correlation between the occurrence of Bunina bodies and that of TDP-43-positive NCIs [12]. In the present patient, the lack of Bunina bodies was considered concordant with the sparse nature of TDP-43 deposits.

On the other hand, the present patient showed rather widespread TDP-43 pathology in the CNS non-motor neurons; although mild, the presence of cerebral cortical TDP-43 pathology suggests possible overlap between motor neuron disease and FTLD [20]. p62, a multifunctional protein related to protein degradation via the proteasome and autophagy, has been shown to physiologically bind to TDP-43, and is likely to be involved in the degradation of fragmented TDP-43 [19]. Disruption of this TDP-43–p62 interaction and subsequent aggregation of pTDP-43 could be a plausible pathomechanism underlying usual sporadic ALS [19], as well as ALS with heterozygous *SQSTM1* mutations [20]. In the present patient, however, such an explanation would not have been applicable to the LMNs. At present, it is tempting to speculate that the compound heterozygous *SQSTM1* mutations could have caused ALS with the different topographical distributions of p62 and TDP-43 described above. However, whether or not such a pathological picture would occur in all patients with compound heterozygous, or homozygous *SQSTM1* mutations awaits further studies.

Parkinsonism has been observed in 2 out of 14 ALS patients with *SQSTM1* heterozygous mutations [6]. In the autopsied patients mentioned above, neuronal loss was evident in the substantia nigra, although no Lewy bodies were found [20]. At present, we consider the Lewy body pathology in the present patient to have been coincidental.

In conclusion, the present patient with ALS is the first reported to have demonstrated compound heterozygous mutations in the *SQSTM1* gene, and in whom the selective occurrence of NCIs positive for only p62 in the affected LMNs was a characteristic feature. Further autopsy studies will be necessary to explore the molecular pathogenesis of ALS with *SQSTM1* mutations.

References

1. Al-Sarraj S, King A, Troakes C et al (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 122:691–702

2. Brettschneider J, Van Deerlin VM, Robinson JL et al (2012) Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 123:825–839

3. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256

4. Deng HX, Hentati A, Tainer JA et al (1993) Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261:1047–1051

5. Deng HX, Chen W, Hong ST et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–215

6. Fecto F, Yan J, Vemula SP et al (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68:1440–1446

7. Hirano M, Nakamura Y, Saigoh K et al (2013) Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 80:458–463

8. Kuusisto E, Kauppinen T, Alafuzoff I (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34:169–180

9. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208

10. Mackenzie IR, Neumann M, Baborie A et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113

11. McKeith IG, Dickson DW, Lowe J et al (2005) Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872

12. Mori F, Tanji K, Miki Y et al (2010) Relationship between Bunina bodies and TDP-43 inclusions in spinal anterior horn in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 36:345–352

13. Murray ME, DeJesus-Hernandez M, Rutherford NJ et al (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122:673–690

14. Nishihira Y, Tan CF, Onodera O et al (2008) Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 116:169–182

15. Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 20:257–268

16. Rosen DR, Siddique T, Patterson D et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62

17. Rubino E, Rainero I, Chiò A et al (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79:1556–1562

18. Sreedharan J, Blair IP, Tripathi VB et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672

19. Tanji K, Zhang HX, Mori F et al (2012) p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res 90:2034–2042

20. Teyssou E, Takeda T, Lebon V et al (2013) Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol. doi:10.1007/s00401-013-1090-0

21. Vance C, Rogelj B, Hortobágyi T et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211

22. Yokoseki A, Shiga A, Tan CF et al (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 63:538–542